関連する概念動画
01:22Chronic Obstructive Pulmonary Disease
1.5K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.5K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.0K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.9K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.9K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
01:20COPD: Pathogenesis and Clinical Features
589
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
589
こちらも読む
関連記事
共著者、ジャーナル、引用グラフによってこの研究に関連する記事。
並び替え
Same author
Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.
American journal of respiratory and critical care medicine·2026
Same author
Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials.
Pulmonary therapy·2026
Same author
Z-scores for Spirometry Interpretation: Implications for Classifying Impairments in Lung Function.
Annals of the American Thoracic Society·2026
Same author
The Association of Race and Ethnicity with Six-Minute Walk Distance: The Multi-Ethnic Study of Atherosclerosis.
Ethnicity & disease·2026
Same author
Association Between Chronic PM2.5 Exposure and CT-Detected Lung Abnormalities in the SPIROMICS Cohort.
Annals of the American Thoracic Society·2026
Same author
Deep learning-based CT-derived vertebral bone mineral density and metformin therapy: a longitudinal study in the Multi-Ethnic Study of Atherosclerosis.
Skeletal radiology·2026
Same journal
Assisted dying and the silencing of medicine's next generation.
Lancet (London, England)·2026
Same journal
Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.
Lancet (London, England)·2026
Same journal
Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.
Lancet (London, England)·2026
Same journal
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Lancet (London, England)·2026
Same journal
Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.
Lancet (London, England)·2026
慢性閉塞性肺疾患
Stephanie A Christenson1, Benjamin M Smith2, Mona Bafadhel3
1Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, CA, USA.
Lancet (London, England)
|May 9, 2022
まとめ
慢性閉塞性肺疾患 (COPD) は,世界的な健康問題です. 病気 の 原因 と 診断 と 治療 に 関する 最近 の 進歩 は,患者 の 改善 の 希望 を 与え て い ます.
科学分野:
- 肺医学
- 流行病学
- 病理生理学
背景:
- 慢性閉塞性肺疾患 (COPD) は,世界的な罹病率と死亡率の主な原因です.
- タバコの煙や汚染物質などの 吸入された有害粒子への曝露は,COPD の主要な原因です.
- COPD の発症と進行に影響を与える生涯の要因は,ますます認識されています.
研究 の 目的:
- COPDの流行病学,病理生理学,イメージング,診断,治療における最近の進歩をレビューする.
- COPD研究におけるオミクスとイメージングにおけるイノベーションの影響を強調する.
- COPD の患者に及ぼす影響について議論する.
主な方法:
- 最近の科学文献とCOPDの研究の進展のレビュー
- オミックスの発見とイメージング技術の統合
- 疫学データと臨床試験の結果の分析
主要な成果:
- COPDの病理生物学についてより深い洞察を 提供しています
- バイオマーカーベースの戦略は,既存のCOPD治療のターゲティングを改善しています.
- COVID-19はCOPD患者のリスクを悪化させ,医療の提供を妨げています.
結論:
- COPDの理解の進歩は 予防,診断,治療の戦略の改善の道を開いています
- バイオマーカーを用いたパーソナライズド・メディカルアプローチは,COPDの管理に有望である.
- COVID-19の継続的な影響は,COPD患者のための適応的な医療戦略を必要とします.